ATHERSYS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.0044 USD | 0.00% |
|
-2.22% | -78.00% |
| 04-11 | North American Morning Briefing : Stock Futures Edge Lower Ahead of PPI Inflation Gauge | DJ |
| 04-05 | Athersys, Inc. Announces Board Changes | CI |
| Sales 2021 | 5.51M 441M | Sales 2022 | 5.32M 426M | Capitalization | 14.16M 1.13B |
|---|---|---|---|---|---|
| Net income 2021 | -87M -6.96B | Net income 2022 | -72M -5.76B | EV / Sales 2021 | 33.5 x |
| Net cash position 2021 | 27.64M 2.21B | Net cash position 2022 | 353K 28.26M | EV / Sales 2022 | 2.59 x |
| P/E ratio 2021 |
-2.31
x | P/E ratio 2022 |
-0.14
x | Employees | 24 |
| Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 99.23% |
More Fundamentals
* Assessed data
More news
Latest transcript on Athersys, Inc.
More press releases
More news
| 1 week | -2.22% | ||
| Current month | -26.67% | ||
| 1 month | -21.43% | ||
| 3 months | -81.74% | ||
| 6 months | -78.00% | ||
| Current year | -78.00% |
1 week
0.00
0.01
1 month
0.000.01
Current year
0.000.04
1 year
0.001.14
3 years
0.0045.25
5 years
0.00109.50
10 years
0.00109.50
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Tech/Sci/R&D Officer | - | 31/12/96 | |
Kasey Rosado
BRD | Director/Board Member | 50 | 31/07/22 |
Ellen Gurley
IRC | Investor Relations Contact | - | 31/01/23 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Kasey Rosado
BRD | Director/Board Member | 50 | 31/07/22 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/04/24 | 0.0044 | 0.00% | 40,500 |
| 25/04/24 | 0.0044 | -2.22% | 233,798 |
| 24/04/24 | 0.0045 | -2.17% | 147,446 |
| 23/04/24 | 0.0046 | -2.13% | 59,716 |
| 22/04/24 | 0.0047 | +4.44% | 396,725 |
Delayed Quote OTC Markets, April 26, 2024 at 08:42 pm
More quotes
Athersys, Inc. is a biotechnology company focused primarily on the field of regenerative medicine. The Company is engaged in the discovery and development of therapeutic product candidates to address unmet medical needs in multiple disease areas. Its MultiStem (invimestrocel) cell therapy, which is an allogeneic stem cell product candidate, is its lead platform product and is in late-stage clinical development. MultiStem cell therapy includes treatment of critical care indications, neurological conditions, inflammatory and immune disorders, certain pulmonary conditions, cardiovascular disease, and other conditions. MultiStem cell therapy is manufactured from human stem cells obtained from adult bone marrow and these cells are alternatively obtained from other tissue sources. It is conducting a Phase III clinical trial of MultiStem cell therapy for the treatment of ischemic stroke, referred to as MultiStem Administration for Stroke Treatment and Enhanced Recovery Study-2 (MASTERS-2).
Calendar
08/05/2024
- Q1 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -78.00% | 272K | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.74B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- ATHXQ Stock
